22 abr 2021
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the interim analysis of the randomized, double-blind, placebo-controlled, multi-center, phase III clinical study “JUPITER-06” (Clinicaltrials.gov identifier: NCT03829969). Junshi Biosciences will communicate with the regulatory authorities regarding the
(0)
SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the interim analysis of the randomized, double-blind, placebo-controlled, multi-center, phase III clinical study JUPITER-06 (Clinicaltrials.gov identifier: NCT03829969). Junshi Biosciences will communicate with the regulatory authorities regarding the supplemental New Drug Application (sNDA) in the near future.
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
Novocure (NASDAQ:NVCR) hasn t exactly been the kind of stock that fired up investors very much throughout most of 2021. That changed recently, though, with good news providing a huge catalyst for the stock. In this
Motley Fool Live video
recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why investors are now really excited about Novocure.
Keith Speights: Shares of Novocure, ticker there is NVCR, jumped 50% last Thursday.
GSK and Vir announce EMA review of VIR-7831 for early treatment of Covid-19 pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.